Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status
  5. Marketed
  6. Revised Labelling

Revised Labelling

Evaluate

June 05, 2023

Asco 2023 – Enhertu hits with pan approach

Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.

Thumbnail
June 03, 2023

Asco 2023 – a role for immuno-oncology in ovarian cancer at last?

Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

Article image
Vantage logo
June 02, 2023

Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats

The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.

Article image
Vantage logo
May 22, 2023

Intercept’s Nash exit feels inevitable

Article image
Vantage logo
May 17, 2023

Astra knocks another hole in J&J's Mariposa plan

Article image
Vantage logo
May 02, 2023

The sellside hacks back Lynparza’s prostate opportunity

The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.

Article image
Vantage logo
March 27, 2023

Natalee delivers Novartis a much-needed win

Article image
Vantage logo
March 23, 2023

Dupixent pushes towards a big new use

Article image
Vantage logo
March 10, 2023

Polivy adcom: no overall survival, no problem

A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.

Article image
Vantage logo
March 09, 2023

Roche is losing its perioperative lung cancer lead

Article image
Vantage logo
January 27, 2023

What Abecma does Carvykti might do better

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up